Literature DB >> 3928396

Recombinant immune interferon inhibits leukemic cell growth by a monocyte-macrophage-mediated mechanism.

T Hosoi, K Ozawa, M Ohta, T Okabe, A Urabe, F Takaku.   

Abstract

We have investigated direct and monocyte-macrophage (Mono/M phi)-mediated indirect effects of recombinant immune interferon (IFN-gamma) on the growth of established leukemic cell lines (K562, KG1, ML1, HL60, U937, and THP1). The direct antiproliferative effects of IFN-gamma on these leukemic cells were mild or negligible, when estimated by 3H-thymidine incorporation. Indirect effects were assessed by the growth pattern of leukemic cells cocultured with Mono/M phi that were pretreated with INF-gamma. While the leukemic cell growth was slightly suppressed by untreated Mono/M phi, this suppression was significantly augmented by the treatment of Mono/M phi with IFN-gamma (10-10,000 U/ml). In addition, the indirect effects of IFN-gamma on leukemic cell growth were examined at different stages of maturation of Mono/M phi. The augmentation of cytotoxicity was detected only when mature Mono/M phi were treated with INF-gamma. This suggests that IFN-gamma acts on tissue macrophages and augments their cytotoxicity against leukemic cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928396

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  2 in total

1.  Recombinant human interferons alpha, beta and gamma reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells.

Authors:  H R Maurer; H T Hassan; C Tsiriyotis; D A Spandidos
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Binding properties and proliferative effects of human recombinant granulocyte-macrophage colony-stimulating factor in primary leukemia and lymphoma.

Authors:  Y F Piao; S Chiba; A Tojo; A Urabe; N Nara; K Miyazono; F Takaku
Journal:  Jpn J Cancer Res       Date:  1989-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.